Financial Performance - The net loss for the nine months ended September 30, 2024 was $53,186 thousand, compared to a net loss of $46,651 thousand for the same period in 2023, representing an increase of approximately 14%[14]. - For the three months ended September 30, 2024, Nautilus Biotechnology reported a net loss of $16.446 million, compared to a net loss of $15.878 million for the same period in 2023, reflecting an increase in losses of approximately 3.6%[18]. - The company reported total operating expenses of $61,496 thousand for the nine months ended September 30, 2024, compared to $56,151 thousand for the same period in 2023, an increase of approximately 9.5%[14]. - Cash used in operating activities for the nine months ended September 30, 2024, was $44.836 million, compared to $37.811 million for the same period in 2023, indicating an 18.4% increase in cash outflow[22]. Assets and Liabilities - Total current assets decreased from $176,837 thousand as of December 31, 2023 to $144,205 thousand as of September 30, 2024, a decline of approximately 18.4%[11]. - Cash and cash equivalents decreased from $19,397 thousand as of December 31, 2023 to $4,409 thousand as of September 30, 2024, a decrease of approximately 77.3%[11]. - Total liabilities decreased from $40,212 thousand as of December 31, 2023 to $36,270 thousand as of September 30, 2024, a reduction of approximately 9.7%[12]. - The company’s total stockholders' equity decreased from $265,353 thousand as of December 31, 2023 to $223,434 thousand as of September 30, 2024, a decline of approximately 15.8%[13]. Accumulated Deficit - The company’s accumulated deficit increased from $202,239 thousand as of December 31, 2023 to $255,425 thousand as of September 30, 2024, an increase of approximately 26.3%[13]. - The company had an accumulated deficit of $255.425 million as of September 30, 2024, compared to $185.215 million as of September 30, 2023, representing an increase in the deficit of approximately 37.8%[19]. Research and Development - Research and development expenses for the three months ended September 30, 2024 were $12,288 thousand, compared to $11,996 thousand for the same period in 2023, reflecting an increase of 2.4%[14]. - The company has been focused on research and development activities related to its proteomics platform since its incorporation in 2016[24]. Stock and Equity - The weighted-average shares used in computing net loss per share attributable to common stockholders for the nine months ended September 30, 2024 was 125,302,440, compared to 124,896,975 for the same period in 2023[14]. - The company issued 367,813 shares of common stock upon the exercise of vested stock options during the nine months ended September 30, 2024, raising $415,000[22]. - The total additional paid-in capital increased to $478.115 million as of September 30, 2024, from $464.509 million as of September 30, 2023, marking an increase of approximately 2.6%[19]. - The total potentially dilutive common share equivalents increased to 17,484,880 from 14,710,602 year-over-year[84]. Cash and Investments - Nautilus Biotechnology's cash, cash equivalents, and restricted cash at the end of the period on September 30, 2024, was $5.411 million, down from $75.106 million at the end of September 30, 2023, a decrease of approximately 92.8%[22]. - As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $221.2 million[139]. - The carrying amount of cash equivalents approximates fair value due to short maturities of these instruments[139]. Risks and Future Financing - The company may require additional equity or debt financing in the future, depending on growth rate and research and development spending[30]. - The company is subject to risks similar to pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals and the need for adequate financing[34]. - The company is exposed to inflation risk, which has impacted labor and goods costs, potentially affecting future operational expenses[140]. Accounting and Reporting - The company is evaluating the impact of new accounting standards on its consolidated financial statements, including ASU 2023-07 and ASU 2023-09[50][51]. - The company’s estimates and assumptions in financial reporting may differ from actual results, impacting future financial statements[31]. - The company had no income tax expense or benefit recognized for the three and nine months ended September 30, 2024, due to a full valuation allowance against deferred tax assets[61].

NAUTILUS" BIOTECHNOLOGY Delivering on the Promise of the Proteome OCTOBER 29, 2024 Safe harbor This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the protein analysis market; Nautilus Biotechnology's anticipated total addressable market; the performance, value and enabling nature of Nautilus Biotechnology's proteomics and pr ...

Financial Performance - Net loss for Q3 2024 was $16.4 million, compared to a net loss of $15.9 million in Q3 2023[4] - Operating expenses for Q3 2024 were $19.1 million, flat compared to Q3 2023[3] - The company reported a net cash used in operating activities of $44.8 million for the nine months ended September 30, 2024, compared to $37.8 million for the same period in 2023[15] Cash and Investments - Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024[4] - Cash, cash equivalents, and restricted cash at the end of the period were $5.4 million, down from $75.1 million at the end of Q3 2023[15] Expenses - Research and development expenses for Q3 2024 were $12.3 million, up from $12.0 million in Q3 2023[13] - General and administrative expenses for Q3 2024 were $6.8 million, down from $7.1 million in Q3 2023[13] Assets and Liabilities - Total assets decreased to $259.7 million as of September 30, 2024, from $305.6 million at the end of 2023[11] - Total liabilities decreased to $36.3 million as of September 30, 2024, from $40.2 million at the end of 2023[11] Strategic Focus - The company is focused on advancing its single-molecule proteome analysis platform, which is expected to enhance research capabilities in proteomics[2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-1541723 ...

Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2024 Financial Results SEATTLE, WA, July 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single- molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Address of principal executive offices) (Zip Code) (206) 333-2001 (Regis ...

Exhibit 99.1 Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, WA, April 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus. "We remain incredibly focused on increasing the scale, stability, and reproducibil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...

Exhibit 99.1 Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results SEATTLE, WA, February 28, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. "2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2 ...

PART I. FINANCIAL INFORMATION [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) Nautilus Biotechnology, Inc. reported net losses of $15.9 million for Q3 2023 and $46.7 million for the nine months, driven by increased operating expenses [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $318.3 million, liabilities increased to $41.1 million, and stockholders' equity decreased to $277.3 million as of September 30, 2023 Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2023 | Dec 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $74,104 | $114,523 | | Short-term investments | $109,185 | $69,948 | | Long-term investments | $92,439 | $129,169 | | **Total Assets** | **$318,336** | **$350,052** | | **Liabilities & Equity** | | | | Total Liabilities | $41,063 | $35,128 | | Accumulated deficit | $(185,215) | $(138,564) | | **Total Stockholders' Equity** | **$277,273** | **$314,924** | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net loss increased to $15.9 million for Q3 2023 and $46.7 million for the nine months, primarily due to higher research and development expenses Operating Results (in thousands, except per share data) | Metric | Q3 2023 | Q3 2022 | Nine Months 2023 | Nine Months 2022 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $11,996 | $9,571 | $34,785 | $28,085 | | General and administrative | $7,079 | $6,249 | $21,366 | $19,229 | | **Total operating expenses** | **$19,075** | **$15,820** | **$56,151** | **$47,314** | | Interest income | $3,197 | $1,889 | $9,517 | $2,929 | | **Net loss** | **$(15,878)** | **$(14,063)** | **$(46,651)** | **$(44,515)** | | Net loss per share | $(0.13) | $(0.11) | $(0.37) | $(0.36) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities increased to $37.8 million, while investing activities shifted to a $2.7 million use, resulting in a $40.4 million decrease in cash for the nine months Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Cash Flow Activity | 2023 | 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | $(37,811) | $(35,429) | | Net cash (used in) provided by investing activities | $(2,675) | $38,315 | | Net cash provided by financing activities | $115 | $427 | | **Net (decrease) increase in cash** | **$(40,371)** | **$3,313** | | Cash at beginning of period | $115,477 | $186,461 | | **Cash at end of period** | **$75,106** | **$189,774** | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's development-stage proteomics platform, confirm sufficient cash for 12 months, and outline accounting policies, investments, and lease commitments totaling $48.2 million - The company is a development-stage biotechnology firm focused on its proteomics platform, with all resources devoted to R&D, business planning, IP, and raising capital[31](index=31&type=chunk) - Management believes that its cash, cash equivalents, and short-term investments of **$183.3 million** as of September 30, 2023, are sufficient to fund operations for the next twelve months[37](index=37&type=chunk) - As of September 30, 2023, the company had total future minimum lease payments of **$48.2 million**, with a weighted-average remaining lease term of **6.9 years**[86](index=86&type=chunk)[88](index=88&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's development-stage proteomics platform, plans for a 2024 commercial launch, increased operating expenses, and strong liquidity with $183.3 million in cash and investments - Nautilus is a development stage company creating a platform technology for quantifying the proteome and has not yet generated any revenue[96](index=96&type=chunk)[97](index=97&type=chunk) - The company plans a three-phase commercial launch, with the second phase of early access engagements and associated revenue anticipated in **2024**, leading to a broader commercial launch[100](index=100&type=chunk) - As of September 30, 2023, the company had **$183.3 million** in cash, cash equivalents, and short-term investments, which is believed to be sufficient to fund operations for at least the next **12 months**[105](index=105&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Operating expenses increased significantly in Q3 2023 and for the nine months, driven by higher R&D and G&A costs due to increased headcount and facilities expenses Comparison of Operating Expenses (in thousands) | Expense Category | Q3 2023 | Q3 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $11,996 | $9,571 | $2,425 | 25% | | General and administrative | $7,079 | $6,249 | $830 | 13% | | **Total operating expenses** | **$19,075** | **$15,820** | **$3,255** | **21%** | Comparison of Operating Expenses (Nine Months, in thousands) | Expense Category | 2023 | 2022 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Research and development | $34,785 | $28,085 | $6,700 | 24% | | General and administrative | $21,366 | $19,229 | $2,137 | 11% | | **Total operating expenses** | **$56,151** | **$47,314** | **$8,837** | **19%** | - The increase in R&D expenses for Q3 2023 was primarily due to a **$1.4 million** increase in salaries and benefits, a **$1.1 million** increase in lab supplies, and a **$0.9 million** increase in facilities costs, partially offset by a **$1.0 million** decrease in external development services[120](index=120&type=chunk)[121](index=121&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity is strong with $275.7 million in cash and investments, sufficient for 12 months, but substantial additional funding will be required for future R&D and commercialization - As of September 30, 2023, the company had cash, cash equivalents and investments of **$275.7 million**[129](index=129&type=chunk) - Net cash used in operating activities was **$37.8 million** for the nine months ended September 30, 2023, primarily resulting from the net loss of **$46.7 million**, offset by non-cash charges like stock-based compensation[135](index=135&type=chunk)[136](index=136&type=chunk) - The company expects to require substantial additional funding for future operations and may seek it through equity or debt financing, though access to capital could be impacted by worsening global economic conditions[133](index=133&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=35&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risks are interest rate fluctuations, potentially impacting marketable debt securities by $1.7 million, and inflation affecting operational costs - The company's primary market risks are interest rate fluctuations and inflation[150](index=150&type=chunk) - A hypothetical **1.00% (100 basis point)** change in interest rates would change the fair value of the company's marketable debt securities by **$1.7 million** as of September 30, 2023[151](index=151&type=chunk) - Inflation affects the company by increasing the cost of labor, goods, and services, and the company may not be able to fully offset these increased costs[152](index=152&type=chunk) [Item 4. Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2023, with no material changes to internal control over financial reporting during the quarter - Based on an evaluation as of September 30, 2023, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were **effective** at a reasonable assurance level[154](index=154&type=chunk) - There were no changes in internal control over financial reporting during the quarter ended September 30, 2023, that materially affected, or are reasonably likely to materially affect, the company's internal controls[155](index=155&type=chunk) PART II - OTHER INFORMATION [Item 1. Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings expected to have a material adverse effect on its business or financial condition - The company is not currently a party to any legal proceedings that would individually or in the aggregate have a **material adverse effect** on its business[158](index=158&type=chunk) [Item 1A. Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) The company faces numerous risks as a development-stage firm, including commercialization challenges, intense competition, supply chain issues, intellectual property protection, regulatory hurdles, and stock price volatility [Risks Related to Our Business](index=39&type=section&id=Risks%20Related%20to%20Our%20Business) Key business risks include a history of losses, dependence on the Nautilus platform's commercialization, intense competition, manufacturing challenges, and the need for additional capital - The company is a development stage entity with a history of net losses, no commercialized products, and its success is entirely dependent on the Nautilus platform, which is still in development[175](index=175&type=chunk)[176](index=176&type=chunk) - The company may not be able to successfully manufacture its products at scale, as it has no experience and relies on **single-source suppliers** for critical components like reagents and antibodies[190](index=190&type=chunk)[196](index=196&type=chunk) - The life sciences technology market is highly competitive, with rivals having greater financial resources, brand recognition, and established sales channels[199](index=199&type=chunk)[200](index=200&type=chunk) [Risks Related to Our Intellectual Property](index=50&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) Intellectual property risks include challenges in obtaining and maintaining patent protection, uncertainties in patent law, global IP enforcement difficulties, and protecting trade secret confidentiality - The company's ability to successfully commercialize its products may be impaired if it cannot obtain and maintain sufficient intellectual property protection, as competitors could develop similar products[225](index=225&type=chunk) - Changes in U.S. patent law and court decisions regarding the patentability of life sciences inventions create uncertainty and could adversely impact the company's existing or future patents[230](index=230&type=chunk)[231](index=231&type=chunk) - The company relies on trade secrets and confidentiality agreements, which can be difficult to protect and may not prevent unauthorized disclosure or independent development of similar technologies by competitors[246](index=246&type=chunk) [Risks Related to Litigation](index=59&type=section&id=Risks%20Related%20to%20Litigation) Litigation risks include costly IP enforcement or defense, potential loss of rights, and product liability claims from undetected defects in the Nautilus platform - The company may become involved in expensive and time-consuming litigation to enforce its IP rights or defend against infringement claims, which could result in loss of rights or significant damages[268](index=268&type=chunk)[269](index=269&type=chunk) - The Nautilus platform's complex technology may contain undetected defects or errors, which could lead to product liability claims, warranty costs, and damage to the company's brand reputation[270](index=270&type=chunk) [Risks Related to Regulatory and Legal Compliance Matters](index=60&type=section&id=Risks%20Related%20to%20Regulatory%20and%20Legal%20Compliance%20Matters) Regulatory risks include potential FDA oversight for RUO products, compliance with complex data privacy and anti-corruption laws, and environmental health and safety liabilities - While currently sold as Research Use Only (RUO), the company's products could become subject to FDA regulation as medical devices, which would require a lengthy and expensive premarket clearance or approval process[274](index=274&type=chunk)[275](index=275&type=chunk)[281](index=281&type=chunk) - The company is subject to various U.S. federal and state laws regarding data privacy and security, such as the CCPA and HIPAA, and failure to comply could result in **significant fines** and harm to the business[288](index=288&type=chunk)[289](index=289&type=chunk)[290](index=290&type=chunk) - Expansion of commercial activities outside the U.S. would subject the company to anti-corruption laws like the FCPA, where violations could lead to **civil or criminal penalties**[295](index=295&type=chunk) [Risks Related to our Operations](index=67&type=section&id=Risks%20Related%20to%20our%20Operations) Operational risks include IT system disruptions, data breaches, dependence on key personnel, talent competition, managing growth, and global supply chain interruptions - The company relies on IT systems that are vulnerable to cybersecurity attacks and data breaches, which could lead to the loss of trade secrets, litigation, and **significant liability**[304](index=304&type=chunk)[305](index=305&type=chunk) - The company is highly dependent on its senior management and key scientific personnel, particularly founders Sujal Patel (CEO) and Parag Mallick (Chief Scientist), and the loss of their services could harm the business[312](index=312&type=chunk)[313](index=313&type=chunk) - Global supply chain interruptions, exacerbated by political tensions, could negatively impact the development and commercialization of the company's products[322](index=322&type=chunk) [Risks Related to Our Common Stock](index=71&type=section&id=Risks%20Related%20to%20Our%20Common%20Stock) Common stock risks include high price volatility, significant influence by principal stockholders, potential dilution from future share sales, and no anticipated dividends - The market price of the company's Common Stock has been and may continue to be **highly volatile** due to factors such as operating results, product development timelines, and broader market conditions[329](index=329&type=chunk) - As of September 30, 2023, directors, executive officers, and holders of more than 5% of common stock collectively owned approximately **69.0%** of outstanding shares, giving them significant influence over stockholder matters[335](index=335&type=chunk) - The company does not anticipate paying any dividends in the foreseeable future and plans to retain earnings to fund operations and growth[338](index=338&type=chunk) [General Risk Factors](index=75&type=section&id=General%20Risk%20Factors) General risks include public company compliance costs, limitations on NOL utilization, internal control failures, and reduced disclosure requirements as an emerging growth company - Operating as a public company results in **significant legal, accounting, and compliance expenses**, which will increase further once the company is no longer an "emerging growth company"[346](index=346&type=chunk) - The company's ability to use its federal and state net operating loss carryforwards (NOLs) may be limited by Section 382 of the Internal Revenue Code due to ownership changes[350](index=350&type=chunk) - The company is an "emerging growth company" and a "smaller reporting company," which allows for reduced disclosure requirements that may make its common stock less attractive to investors[358](index=358&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=79&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the reporting period - None[363](index=363&type=chunk) [Item 3. Defaults Upon Senior Securities](index=79&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities occurred during the reporting period - None[364](index=364&type=chunk) [Item 4. Mine Safety Disclosures](index=79&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - None[365](index=365&type=chunk) [Item 5. Other Information](index=79&type=section&id=Item%205.%20Other%20Information) No other information was reported during the period - None[366](index=366&type=chunk) [Item 6. Exhibits](index=80&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate governance documents, employment agreements, and officer certifications - Lists exhibits filed with the report, including corporate governance documents, employment agreements, and SEC-required certifications[368](index=368&type=chunk)[369](index=369&type=chunk)